These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34264142)

  • 1. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
    Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
    Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotherapies in Uveitis.
    Leclercq M; Desbois AC; Domont F; Maalouf G; Touhami S; Cacoub P; Bodaghi B; Saadoun D
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33171664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert opinion on the use of biological therapy in non-infectious uveitis.
    Touhami S; Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
    Expert Opin Biol Ther; 2019 May; 19(5):477-490. PubMed ID: 30888881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].
    Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
    Rev Med Interne; 2018 Sep; 39(9):687-698. PubMed ID: 29610003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ocular manifestations in Behçet's disease].
    Desbois AC; Terrada C; Cacoub P; Bodaghi B; Saadoun D
    Rev Med Interne; 2018 Sep; 39(9):738-745. PubMed ID: 29625716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
    Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
    Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis.
    Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD
    Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future treatments for Behçet's uveitis: road to remission.
    Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
    Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics in the Treatment of Uveitis.
    Dingerkus VLS; Becker MD; Doycheva D
    Klin Monbl Augenheilkd; 2022 May; 239(5):686-694. PubMed ID: 35426112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
    Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
    Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
    Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
    Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
    Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis.
    Garweg JG; Straessle KA
    Ocul Immunol Inflamm; 2024 May; ():1-8. PubMed ID: 38709218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
    Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
    Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behçet's disease uveitis: is there a need for new emerging drugs?
    Tugal-Tutkun I; Çakar Özdal P
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):531-547. PubMed ID: 33147420
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis.
    Juan HY; Sheu SJ; Hwang DK
    J Ocul Pharmacol Ther; 2024 Sep; ():. PubMed ID: 39315932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.